10-Q: Lyell Immunopharma Reports Reduced Loss, LYL314 Progress

Lyell Immunopharma reported a reduced net loss in Q2 2025, highlighted positive early clinical data for LYL314 in lymphoma, and secured $50 million in new financing.

Summary

• Lyell Immunopharma, a late-stage clinical cell therapy company, reported a net loss of $94.879 million for the six months ended June 30, 2025, an improvement from a net loss of $106.476 million for the same period in 2024.
• Research and development expenses decreased by $5.1 million to $78.304 million for the six months ended June 30, 2025, primarily due to reduced research activities, collaborations, and outside services.
• General and administrative expenses decreased by $1.9 million to $23.832 million for the six months ended June 30, 2025, mainly due to lower stock-based compensation and legal expenses.
• The company's lead product candidate, LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, is currently in a pivotal PiNACLE trial for 3L+ large B-cell lymphoma (LBCL) and a Phase 1/2 study in the 2L setting.
• New clinical data from the Phase 1/2 trial of LYL314, presented in June 2025, showed an 88% overall response rate (ORR) and 72% complete response (CR) in 3L+ LBCL patients (N=25), with 71% of CR patients remaining in CR at 6 months.
• Initial data for LYL314 in 2L LBCL patients (N=11) showed a 91% ORR and 64% CR, with 100% of CR patients remaining in CR at last assessment.
• LYL314 demonstrated a manageable safety profile, with low rates of Grade 1 (22%) or Grade 2 (35%) cytokine release syndrome (CRS) and Grade >3 immune effector cell-associated neurotoxicity syndrome (ICANS) in 14% of patients, with no deaths related to LYL314 administration.
• A clinical milestone related to the ImmPACT Bio USA Inc. acquisition was achieved, triggering the issuance of 625,000 common shares in July 2025.
• The company completed a private placement financing in July 2025, raising approximately $50.0 million gross proceeds from the sale of 3,753,752 common shares at $13.32 per share.
• Cash, cash equivalents, and marketable securities totaled $296.8 million as of June 30, 2025, with management believing these funds, including the recent capital raise, will be sufficient to fund operations into mid-2027.
• An impairment charge of $1.4 million was recognized for long-lived assets related to the planned closure of the West Hills, Los Angeles manufacturing facility, following successful technology transfer to the LyFE Manufacturing Center in Bothell, Washington.

Sentiment

Score: 7

Explanation: The company shows positive momentum with reduced losses, promising early clinical data for its lead candidate LYL314, and a successful capital raise that extends its financial runway. While still pre-revenue and facing inherent biotech risks, these developments indicate progress and improved financial stability.

Positives

• Net loss decreased by $11.597 million for the six months ended June 30, 2025, compared to the same period in 2024, indicating improved financial performance.
• Research and development expenses decreased by $5.404 million for the three months and $5.131 million for the six months ended June 30, 2025, reflecting cost management.
• LYL314 demonstrated high overall response rates (88% in 3L+ and 91% in 2L) and complete response rates (72% in 3L+ and 64% in 2L) in early clinical data, suggesting strong efficacy.
• The safety profile of LYL314 was manageable, with low rates of severe CRS and ICANS, making it potentially suitable for outpatient administration.
• LYL314 received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, which could expedite development and regulatory review.
• The successful technology transfer to the LyFE Manufacturing Center in Bothell, Washington, is expected to provide sufficient drug supply for ongoing and planned trials and potential commercial launch, with a capacity of over 1,200 patient CAR T-cell products per year.
• The recent $50.0 million private placement financing extends the company's cash runway into mid-2027, providing crucial liquidity for continued operations and clinical development.

Negatives

• The company continues to incur substantial net losses, with an accumulated deficit of $1.44 billion as of June 30, 2025.
• Interest income, net, significantly decreased by $3.088 million for the three months and $6.045 million for the six months ended June 30, 2025, due to decreased interest rates and lower cash balances.
• Net cash used in operating activities increased to $89.196 million for the six months ended June 30, 2025, compared to $80.110 million in the prior year, indicating higher cash burn.
• An impairment charge of $1.443 million was recognized for long-lived assets related to the closure of the West Hills, Los Angeles manufacturing facility.
• The company has no products approved for sale and has never generated revenue from product sales, relying heavily on financing for operations.
• The recent capital raise, while extending liquidity, also resulted in dilution to existing stockholders.

Risks

• The company will require substantial additional capital to achieve its goals, and failure to obtain it could force delays or termination of product development.
• Milestone, royalty, and success payment obligations may result in dilution to stockholders or reduce cash resources.
• The company may never realize the full value of its long-lived assets, potentially leading to future material impairment charges.
• Inability to successfully develop, manufacture, and commercialize product candidates or significant delays in doing so could harm the business.
• Product candidates and technology platforms are based on novel, unproven technologies, exposing the company to unforeseen risks and making development time/cost difficult to predict.
• The company is highly dependent on key personnel, and failure to attract and retain them could harm business strategy.
• Lack of marketing, sales, or distribution infrastructure poses substantial risks for commercialization.
• Compromised information technology systems or data could lead to regulatory actions, litigation, and business disruptions.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business and operations.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.
• Delays in qualifying or receiving regulatory approvals for manufacturing facilities, or expanding capacity, could delay development plans.
• The complexity of cellular therapy manufacturing poses risks of increased costs, program delays, or supply limitations.
• Reliance on third parties for manufacturing and clinical trials subjects the company to risks and could delay or prevent development/commercialization.
• Dependence on patient enrollment and retention in clinical trials; delays or difficulties could materially adversely affect research and development.
• Substantial competition in rapidly changing industries may result in others commercializing products more successfully.
• Cellular therapy product candidates represent new therapeutic approaches, potentially leading to heightened regulatory scrutiny and delays.
• Results from early clinical trials are not necessarily predictive of future results, and later trials may fail to produce positive outcomes.
• Interim, topline, or preliminary data may change as more patient data become available or manufacturing processes change.
• Inability to successfully integrate acquired businesses, such as ImmPACT, or realize anticipated benefits.
• Inability to obtain and maintain sufficient intellectual property protection or if the scope is not broad enough.
• Breach of in-licensed intellectual property agreements could lead to loss of development/commercialization ability.
• Potential lawsuits for infringing or misappropriating third-party intellectual property rights could be costly and time-consuming.
• Lifespans of patents may not be sufficient to effectively protect products and business.
• Inability to protect intellectual property rights throughout the world.
• Claims challenging the inventorship of patents and other intellectual property.
• Inability to protect the confidentiality of trade secrets and other proprietary information.
• Claims that employees, consultants, or contractors breached non-compete/non-solicit obligations or wrongfully used confidential information.
• Inability to comply with Nasdaq Global Select Market continued listing requirements.
• Sales of a substantial number of shares by existing stockholders could cause stock price decline.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights.
• Future acquisitions, strategic investments, partnerships, or alliances could be difficult to integrate, divert management, and dilute stockholder value.
• Requirements of being a public company divert management time and strain resources.
• Delaware law and company charter/bylaws might discourage, delay, or prevent a change in control.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Failure to maintain proper and effective internal controls over financial reporting or identify additional material weaknesses.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts publish negative or neutral evaluations, stock price could decline.
• Changes in tax laws or regulations may have a material adverse effect.
• Indemnity provisions in various agreements potentially expose the company to substantial liability.

Future Outlook

The company expects to provide an update on the pivotal PiNACLE trial progress in late 2025, present more mature data from the Phase 1/2 trial for 2L LBCL patients in late 2025, and initiate a Phase 3 randomized controlled trial for 2L LBCL patients by early 2026. The first IND submission for a fully-armed CAR T-cell product candidate for solid tumors is expected in 2026. Management believes existing cash, cash equivalents, and marketable securities, including the recent private placement proceeds, will fund operations into mid-2027.

Management Comments

• We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
• Our lead program, LYL314, is targeting patients with aggressive relapsed and/or refractory large B-cell non-Hodgkin lymphoma (NHL).
• LYL314 is designed with a true OR logic gate to target B cells that express either CD19 or CD20 with full potency and is manufactured with a process that enriches for CD62L-positive cells to generate more naive and central memory CAR T cells with enhanced stemlike features and antitumor activity.
• We believe it is critically important to control and continuously monitor all aspects of the cell therapy manufacturing process to mitigate risks.
• Our LyFE Manufacturing Center located in Bothell, Washington, at full staffing and capacity, is expected to be able to manufacture >1,200 patient CAR T-cell products/year and support our clinical development needs and early commercial launch.
• We expect to incur additional losses in the foreseeable future as we conduct and expand our research and development efforts.
• We believe that our existing cash, cash equivalents and marketable securities as of June 30, 2025 will be adequate to fund our operations at least through the next 12 months from the date these unaudited condensed consolidated financial statements are issued.

Industry Context

The company operates in the highly competitive and rapidly evolving cell therapy and biotechnology industries, focusing on CAR T-cell therapies for hematologic malignancies and solid tumors. While first-generation CD19 CAR T-cell therapies have advanced B-cell lymphoma treatment, there remains a significant unmet need for more complete and durable responses, particularly in patients who are refractory or relapse. The company's dual-targeting LYL314 aims to address CD19 antigen escape and improve outcomes. For solid tumors, which account for 90% of cancer deaths, the industry faces challenges with T-cell exhaustion, lack of durable stemness, and hostile tumor microenvironments, which Lyell aims to overcome with its 'fully-armed' CAR T-cell candidates. The macroeconomic environment, including inflation and geopolitical conflicts, continues to impact the broader industry.

Comparison to Industry Standards

• LYL314's dual-targeting CD19/CD20 design is intended to overcome limitations of single-targeting CD19 CAR T-cell therapies, such as CD19 antigen escape, which is a known mechanism contributing to disease relapse in approved therapies.
• The manufacturing process for LYL314 enriches for CD62L-positive naive and central memory T cells, which has been associated with better engraftment, improved persistence, and reduced exhaustion compared to CAR T cells generated from traditional processes, as observed in data from trials like ZUMA-7 for axicabtagene ciloleucel.
• In 3L+ LBCL, LYL314 achieved a 72% complete response rate, which compares favorably to the industry context where more than 40% of patients treated with approved CD19 CAR T-cell therapies are not disease-free after treatment, and 30% do not respond at all.
• The reported 71% of complete responders remaining in complete response at 6 months for 3L+ LBCL patients with LYL314 suggests a potentially more durable response compared to approved CD19 CAR T-cell therapies where approximately 50% of patients progress or die within six months.
• The manageable safety profile of LYL314, with low rates of severe CRS and ICANS, is appropriate for outpatient administration, potentially offering a more favorable treatment experience compared to some existing CAR T-cell therapies that often require intensive inpatient monitoring.

Management Changes

Legal Proceedings

• Not currently party to any material legal proceedings or aware of any such proceedings contemplated by a government authority or otherwise.

Related Party Transactions

• The company has a sublease agreement with Sonoma Biotherapeutics, Inc., a related party with common stockholders and board members. Sublease income from Sonoma was $1.389 million for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from the recent capital raise and future capital raises, but also benefit from extended cash runway and positive clinical data.
• Employees: Workforce reductions in late 2023, 2024, and early 2025 may impact morale and retention, but new key hires (CMO, General Counsel) indicate strategic rebuilding.
• Patients: Positive early clinical data for LYL314 offers hope for improved treatment options for large B-cell lymphoma, particularly for those with primary refractory disease.
• Creditors: Extended cash runway improves the company's ability to meet financial obligations.
• Suppliers/Partners: Continued reliance on third parties for manufacturing and clinical trials, with risks related to supply chain and compliance.

Next Steps

• Expand the number of trial sites for the pivotal PiNACLE trial up to approximately 35 to accelerate enrollment.
• Provide an update on the PiNACLE trial progress in late 2025.
• Present more mature data from the ongoing Phase 1/2 trial for patients receiving treatment in the 2L setting in late 2025.
• Initiate a Phase 3 randomized controlled trial in patients receiving treatment in the 2L setting with relapsed and/or refractory LBCL by early 2026.
• Submit the first IND for a fully-armed CAR T-cell product candidate with an undisclosed target for solid tumors in 2026.

Key Dates

Recommendation

Lyell Immunopharma has demonstrated promising early clinical data for LYL314, which could be a significant advancement in CAR T-cell therapy for lymphoma. The recent capital raise provides a longer cash runway, mitigating immediate liquidity concerns. However, the company remains in early to mid-stage clinical development, is pre-revenue, and continues to incur substantial operating losses. The inherent risks of clinical trial success, regulatory approval, and commercialization in the highly competitive biotechnology sector remain high. While the positive clinical signals are encouraging, the long path to profitability and potential future dilution warrant a 'hold' recommendation for seasoned investors, balancing the upside potential with significant execution risks.

Keywords

Cell therapy, CAR T-cell, LYL314, Lymphoma, Oncology, Biotechnology, Clinical trials, Immunopharma, Biopharmaceutical, Nasdaq, SEC filing